Pathologic Features and Clinical Outcomes of HER2 FISH Cases with HER2: CEP17 ratio > 2.0 but < 4 HER2 signals/cell; A Multi-Institutional Study

被引：0
|
作者：
Ballard, Morgan [1 ]
Toukatly, Mirna [2 ]
Bean, Gregory [3 ]
Jalikis, Florencia [4 ]
Krings, Gregor [3 ]
Schmidt, Rodney [4 ]
Chen, Yunn-Yi [3 ]
Dintzis, Suzanne
Troxell, Megan [5 ]
West, Robert [6 ]
Sibley, Richard [5 ]
Allison, Kimberly [6 ]
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Univ Washington, Med Ctr, Seattle, WA 98195 USA
[3] UCSF, San Francisco, CA USA
[4] Univ Washington, Seattle, WA 98195 USA
[5] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[6] Stanford Univ, Stanford, CA 94305 USA
来源：
MODERN PATHOLOGY | 2018年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
139
引用
收藏
页码：47 / 48
页数：2
相关论文
共 50 条
  • [41] Relationship between Pathological Features, Her2 Protein Expression, and HER2 and CEP17 Copy Numbers in DCIS.
    Lambein, K.
    Van Bockstal, M.
    Praet, M.
    Denys, H.
    Braems, G.
    Nuyts, A.
    Cocquyt, V.
    Pauweis, P.
    Van Den Broecke, R.
    Libbrecht, L.
    CANCER RESEARCH, 2011, 71
  • [42] HER2 in-Situ hybridization positive breast cancers with HER2/CEP17 ratio ≥2.0 and average HER2 copy number <4.0 are frequently discordant with HER2 immunohistochemistry results: Implications for potential modification of testing algorithm
    Livasy, Chad
    Johnson, Nicole
    Domfeh, Akosua
    CANCER RESEARCH, 2018, 78 (04)
  • [43] Breast Cancers with HER2/CEP17 Ratio ≥2.0 and an Average HER2 Copy Number &lt; 4.0 per Cell: Clinicopathologic Features and Alternative Chromosome 17 Probe Analysis of 102 Cases from a Single Institution Study
    Bai, Qianming
    Zhou, Shuling
    Zhu, Xiaoli
    Zhou, Xiaoyan
    Yang, Wentao
    LABORATORY INVESTIGATION, 2019, 99
  • [44] Breast Cancers with HER2/CEP17 Ratio ≥2.0 and an Average HER2 Copy Number &lt; 4.0 per Cell: Clinicopathologic Features and Alternative Chromosome 17 Probe Analysis of 102 Cases from a Single Institution Study
    Bai, Qianming
    Zhou, Shuling
    Zhu, Xiaoli
    Zhou, Xiaoyan
    Yang, Wentao
    MODERN PATHOLOGY, 2019, 32
  • [45] A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China
    Shuling Zhou
    Hong Lv
    Anqi Li
    Ming Li
    Siyuan Zhong
    Hongfen Lu
    Xiaoyan Zhou
    Qianming Bai
    Wentao Yang
    BMC Cancer, 23
  • [46] Prognostic value of HER2/CEP17 ratio in HER2-positive early breast cancer by FISH testing
    Zheng, F.
    Du, F.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S155 - S155
  • [47] Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features
    Zare, Somaye Y.
    Lin, Leo
    Alghamdi, Abrar G.
    Daehne, Svenja
    Roma, Andres A.
    Hasteh, Farnaz
    Dell'Aquila, Marie
    Fadare, Oluwole
    HUMAN PATHOLOGY, 2019, 83 : 7 - 13
  • [48] HER2 positive breast cancers with HER2:CEP17 ratio ≥2 and copy number &gt;4 and &lt;8 should require additional workup as recommended for Press groups G2-G4 in the 2018 ASCO/CAP HER2 update
    Ericsson, Paula Gonzalez
    Rexer, Brent
    Wheeler, Ferrin
    Yenamandra, Ashwini
    Sanders, Melinda
    MODERN PATHOLOGY, 2019, 32
  • [49] HER2 positive breast cancers with HER2: CEP17 ratio ≥2 and copy number &gt; 4 and &lt; 8 should require additional workup as recommended for Press groups G2-G4 in the 2018 ASCO/CAP HER2 update
    Ericsson, Paula Gonzalez
    Rexer, Brent
    Wheeler, Ferrin
    Yenamandra, Ashwini
    Sanders, Melinda
    LABORATORY INVESTIGATION, 2019, 99
  • [50] Do Decreased CEP17 Signals Indicate the Presence of "Monosomy" in Breast Cancer? A Study of HER2 Gene Status and HER2 Immunohistochemistry.
    Tse, C. H.
    Hwang, H. C.
    Goldstein, L. C.
    Kandalaft, P. L.
    Duesterhoeft, S. M.
    Kussick, S. L.
    Gown, A. M.
    CANCER RESEARCH, 2011, 71
12345